All data are based on the daily closing price as of March 28, 2025
h
Hisamitsu Pharmaceutical
4530.TSE
27.48 USD
-0.04
-0.15%
Overview
Last close
27.48 usd
Market cap
2.02B usd
52 week high
32.56 usd
52 week low
22.74 usd
Target price
30.04 usd
Valuation
P/E
21.782
Forward P/E
N/A
Price/Sales
2.0098
Price/Book Value
1.161
Enterprise Value
1.25B usd
EV/Revenue
1.2524
EV/EBITDA
8.5619
Key financials
Revenue TTM
1.00B usd
Gross Profit TTM
467.67M usd
EBITDA TTM
129.93M usd
Earnings per Share
1.31 usd
Dividend
0.85 usd
Total assets
2.24B usd
Net debt
-664.94M usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.